- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| SANUWAVE HEALTH Aktie jetzt für 0€ handeln | |||||
| Mo | Sanuwave sees Q2 revenue up to $9.8M | 1 | Seeking Alpha | ||
| Mo | Sanuwave: Q2-Umsatz übertrifft Prognose | 2 | Investing.com Deutsch | ||
| Mo | Sanuwave posts Q2 revenue of $9.6M-$9.8M, beating guidance | 1 | Investing.com | ||
| Mo | SANUWAVE Health, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| Mo | SANUWAVE Health, Inc.: Sanuwave Health Reports Preliminary Q2 2026 Revenue of $9.6-$9.8 Million, Above High End of Revised Guidance | 3 | GlobeNewswire (USA) | ||
| 16.06. | SANUWAVE Health, Inc.: Sanuwave Health Updates Second Quarter 2026 Guidance | 141 | GlobeNewswire (Europe) | Sanuwave updates guidance for Q2 2026 to $8.5 - $9.5 million Company on pace for record unit sales of applicators in Q2 Market disruption impacting Ultramist system sales EDEN PRAIRIE, Minn., June... ► Artikel lesen | |
| 15.06. | SANUWAVE Health, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 13.05. | Sanuwave forecasts Q2 revenue of $11.1M-$11.6M while maintaining $51M-$55M full-year outlook | 1 | Seeking Alpha | ||
| 13.05. | SANUWAVE Health Inc Reports Q1 2026 Results: Full Earnings Call Transcript | 3 | Benzinga.com | ||
| 13.05. | SANUWAVE Health reports mixed Q1 results; initiates Q2 and reaffirms FY26 outlook | 2 | Seeking Alpha | ||
| 12.05. | SANUWAVE Health, Inc.: Sanuwave Announces Revenues and Financial Results for Q1 FY2026 | 185 | GlobeNewswire (Europe) | Q1 2026 revenues were $9.6 million, up 3.1% from $9.3 million in Q1 2025. This represents the highest Q1 quarterly revenues in Company history. Q1 2026 gross margin was 77.3%, versus 79.0% in Q1 2025.... ► Artikel lesen | |
| 12.05. | SANUWAVE Health, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 12.05. | SANUWAVE Health, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 20.04. | Sanuwave Health (SNWV) Slipped as CMS Dropped the Coverage Limit | 1 | Insider Monkey | ||
| 16.04. | Sanuwave reports Q1 revenue of $9.6M-$9.7M, up 3-4% year-over-year | 1 | Investing.com | ||
| 16.04. | Sanuwave meldet verlangsamtes Wachstum - Aktie unter Druck | 2 | Investing.com Deutsch | ||
| 16.04. | SANUWAVE Health, Inc.: Sanuwave Health Reports Preliminary Q1 2026 Revenue of $9.6-$9.7 Million, Up 3-4% Year-over-Year | 192 | GlobeNewswire (Europe) | Sanuwave is pleased to announce preliminary revenues of $9.6 million to $9.7 million for the first quarter ended March 31, 2026, in line with prior guidance for Q1. EDEN PRAIRIE, Minn., April 16,... ► Artikel lesen | |
| 16.04. | SANUWAVE Health, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 27.03. | SANUWAVE outlines 16-25% revenue growth target for 2026 as reseller expansion accelerates | 4 | Seeking Alpha | ||
| 27.03. | SANUWAVE Q4 2025: Rekordumsatz, doch Aktie bricht wegen Sorgen ein | 8 | Investing.com Deutsch |
1 2 Weiter >>
31 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SERNOVA BIOTHERAPEUTICS | 0,072 | -8,86 % | Sernova Biotherapeutics, Inc.: Sernova Biotherapeutics Receives FDA Orphan Drug Designation for Autologous Islet Transplantation for Prevention of Diabetes Due to Total Pancreatectomy | TORONTO and BOSTON, June 17, 2026 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics Inc. ("Sernova" or the "Company") (TSX: SVA) (OTC: SEOVF) (FSE/XETRA: PSHO), a leading regenerative medicine company focused... ► Artikel lesen | |
| SONOMA PHARMACEUTICALS | 2,350 | -100,00 % | Sonoma Pharmaceuticals, Inc. - S-8, Securities to be offered to employees in employee benefit plans | ||
| TANDEM DIABETES | 13,100 | -3,68 % | Does TNDM Stock Still Deserve a Place in Your Portfolio? | ||
| VERU | 2,555 | -8,09 % | Top Biotech Gainers: VERU Teams Up With NVO, ABSI On Watch, ALVO Resubmits BLAs To FDA... | REYKJAVIK (dpa-AFX) - Thursday's top gainers include Veru, following a Novo Nordisk collaboration; Health Catalyst, following a divestment of its revenue workflow and analytics software business... ► Artikel lesen | |
| SENSEONICS | 4,560 | -3,39 % | Senseonics Holdings, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results | Generated Q4 revenue of $14.3 million, an increase of 72% year-over-year Received CE Mark approval for commercialization of Eversense 365 in Europe Launched first Eversense 365 AID system integration... ► Artikel lesen | |
| TEMPEST THERAPEUTICS | 0,974 | 0,00 % | Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors | BRISANE, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) ("Tempest" or "Tempest Therapeutics") today announced the appointment of two independent directors, Drake... ► Artikel lesen | |
| VIRIDIAN THERAPEUTICS | 16,800 | -2,89 % | Aktien New York Ausblick: Nasdaq erholt - Comcast-Aufspaltung beflügelt Branche | NEW YORK (dpa-AFX) - Die Anleger dürften den jüngsten Kursrückschlag an der New Yorker Tech-Börse Nasdaq direkt zum Wiedereinstieg nutzen. Im Fokus stehen am Montag die jüngste Entspannung im davor... ► Artikel lesen | |
| SINTX TECHNOLOGIES | 1,560 | -9,30 % | SINTX Technologies, Inc.: SINTX Technologies Announces Receipt of More Than $3.2 Million in Contract Manufacturing Purchase Orders | SALT LAKE CITY, Utah, June 22, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) ("SINTX" or the "Company"), a leader in advanced silicon nitride ceramics and advanced material technologies... ► Artikel lesen | |
| VYOME | 2,220 | -1,77 % | Mitschrift des Earnings Call: Vyome Holdings weist für Q1 2026 eine starke Cash-Position aus | ||
| VIVANI MEDICAL | 1,260 | +5,88 % | Vivani Medical, Inc.: Vivani Medical schließt Vereinbarung mit Novo Nordisk zur Evaluierung von NPM-139, einem miniaturisierten, ultra-langwirkenden Semaglutid-Implantat zur langfristigen Gewichtsregulierung | Novo Nordisk wird eine nicht-exklusive interne Evaluierung der von Vivani hergestellten Semaglutid-Implantate durchführenALAMEDA, Kalifornien, July 08, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc.... ► Artikel lesen | |
| STEREOTAXIS | 1,428 | -3,90 % | Stereotaxis, Inc.: Stereotaxis Completes Acquisition of Robocath | ST. LOUIS and ROUEN, France, July 09, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced... ► Artikel lesen | |
| VIEMED HEALTHCARE | 10,400 | 0,00 % | Reportable, Inc.: Stonegate Capital Partners Updates Coverage on Viemed Healthcare, Inc. (VMD) 1Q26 | Dallas, Texas--(Newsfile Corp. - May 12, 2026) - Viemed Healthcare, Inc. (NASDAQ: VMD). Stonegate Capital Partners Updates Coverage on Viemed Healthcare, Inc. (NASDAQ: VMD). Viemed's 1Q26 results... ► Artikel lesen | |
| VIVOS THERAPEUTICS | 0,419 | 0,00 % | Vivos Therapeutics, Inc. - 8-K, Current Report | ||
| TENON MEDICAL | 0,213 | -5,58 % | Tenon Medical, Inc. - 8-K, Current Report | ||
| SEASTAR MEDICAL | 4,815 | -2,73 % | SeaStar Medical Reports First Quarter Financial Results and Provides Business Updates | Added 7 top-rated children's hospitals to QUELIMMUNE- pediatric acute kidney injury (AKI) customer base, increasing first quarter revenue 69% versus first quarter 2025 revenue Advanced enrollment... ► Artikel lesen |
Das Unternehmen SANUWAVE HEALTH INC kann der Branche Gesundheitswesen zugeordnet werden. Der aktuelle Kurs liegt bei 11,200 Euro und damit -4,11 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SANUWAVE HEALTH INC finden Sie auf Wallstreet Online.